CRAF (RAF1); MAP kinase 3 (MAPK3; ERK-1); β-catenin (CTNNB1); enhancer of zeste homolog 2 (EZH2) BriefCommunication Pages: 127 - 127
Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; KIR; CD158E1) BriefCommunication Pages: 130 - 130
Mycobacterium tuberculosis Rv2660c hypothetical protein (Rv2660c); M. tuberculosis secreted antigen 85-B (fbpB; Ag85B); M. tuberculosis 6 kDa early secretory antigenic target (esxA; Esat6) BriefCommunication Pages: 133 - 133
Mitochondrial permeability transition pore (mPTP); cyclophilin D (CYPD) BriefCommunication Pages: 135 - 135
V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1); parkin (PARK2) BriefCommunication Pages: 136 - 136
Amplicon fusion site (AFS) polymerase chain reaction (PCR) for cancer diagnosis and prognosis BriefCommunication Pages: 139 - 139
Mutant genetic leucine-rich repeat kinase 2 (LRRK2) rat model of Parkinson's disease (PD) BriefCommunication Pages: 143 - 143
Patient-derived induced pluripotent stem (iPS) cells as models for long QT syndrome (LQTS) BriefCommunication Pages: 144 - 144
Chemically modified mRNA to induce expression of therapeutic proteins BriefCommunication Pages: 145 - 145
Transcription activator–like effector (TALE) domain nucleases for genome engineering BriefCommunication Pages: 147 - 147
Near-infrared fluorescent (NIRF) molecule–labeled chlorotoxin analogs for brain tumor imaging BriefCommunication Pages: 148 - 148
Time-lapse fluorescence imaging to monitor disease progression in the brains of animal disease models BriefCommunication Pages: 149 - 149